NovaBay Pharmaceuticals, Inc. provided earnings guidance for the fourth quarter and full fiscal year 2023 . For the quarter, company expects to report net sales of $3.7 million. Operating loss for the fourth quarter of 2023 is expected to be approximately $3.2 million, due primarily to the $2.7 million loss in the DERMAdoctor skincare segment.

For the year, company expected to report net sales of $14.7 million. Operating loss for the 2023 fiscal year is expected to be approximately $7.4 million, which includes a $3.8 million loss in the DERMAdoctor skincare segment.